ADTX stock plunges to 52-week low, touches $0.04

Aditx Therapeutics Inc (ADTX) stock has hit a distressing milestone, tumbling to a 52-week low of $0.04. According to InvestingPro data, the company’s financial health score is rated as WEAK, with concerning metrics showing a current ratio of just 0.09. This latest price level reflects a staggering decline over the past year, with the company’s stock experiencing a precipitous drop of nearly 99.96% from its previous positions. The company is quickly burning through cash and operates with a significant debt burden, as revealed by InvestingPro analysis. Investors have watched with concern as ADTX shares have steadily decreased in value, marking a challenging period for the biotech firm which specializes in developing technologies aimed at improving the health of the immune system. The dramatic 1-year change underscores the volatility and the significant hurdles the company faces in a competitive and fast-evolving industry. With negative gross profit margins and short-term obligations exceeding liquid assets, the company faces substantial challenges ahead. Get access to 16 additional InvestingPro Tips and comprehensive analysis at InvestingPro.

In other recent news, Aditxt, Inc. has announced several significant developments. The company completed a reverse stock split at a ratio of 1-for-250, effective March 17, 2025, aiming to meet Nasdaq’s minimum bid price requirements. Aditxt’s subsidiary, Adimune, Inc., is advancing its autoimmune therapy, ADI-100, toward clinical trials, having completed preclinical studies and manufacturing GMP clinical-grade drug substances. Additionally, Aditxt’s subsidiary Pearsanta, Inc. is preparing for an initial public offering (IPO) with Dominari Securities LLC as the lead underwriter, aiming to support its commercial launch and development of Mitomic® Technology for early cancer detection.

Aditxt has also entered into agreements with Appili Therapeutics, Inc. and Evofem Biosciences (OTC:EVFM), Inc., subject to securing necessary capital and shareholder approvals. The company needs approximately $17 million for each agreement, including $15.2 million to satisfy Evofem’s senior secured noteholder. The merger with Evofem remains uncertain due to the cancellation of a special stockholders meeting. Furthermore, Aditxt held a special meeting where stockholders approved the reverse stock split and adjourned the meeting for further voting on additional proposals. These recent developments reflect Aditxt’s strategic efforts to advance health innovations and expand its market presence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.